FDA Approves Foundayo, the First Oral GLP-1 Pill for Weight Loss
The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1, 2026, making it the first oral GLP-1 medication that can be taken at any time of day without food or water restrictions. Clinical trials showed an average weight loss of 27.3 pounds over 72 weeks at the highest dose.
The U.S. Food and Drug Administration approved Eli Lilly's Foundayo on April 1, 2026. The drug, known generically as orforglipron, is an oral GLP-1 medication for adults with obesity or those who are overweight with weight-related health conditions.
Foundayo is the first oral GLP-1 pill that can be taken at any time of day without restrictions on food or water intake. That sets it apart from rival oral treatments, which require more specific administration schedules.
Clinical trials showed strong results. In the ATTAIN-1 study, participants taking the highest dose and completing the 72-week treatment period lost an average of 27.3 pounds, or 12.4% of body weight. The placebo group lost an average of 2.2 pounds. Across all participants taking Foundayo, regardless of whether they completed the trial, average weight loss was 25 pounds.
The FDA approved the drug through its Commissioner's National Priority Voucher program, a pilot initiative launched in 2025 to speed up review of drugs addressing critical public health needs. Foundayo was approved 50 days after filing, 294 days before its standard deadline. It is the fastest approval of a new molecular entity since 2002.
Eli Lilly has committed to keeping the drug accessible. Patients with commercial insurance may pay as little as $25 per month with a savings card. Self-pay patients start at $149 per month for the lowest dose. Medicare Part D beneficiaries may access it for $50 per month starting July 1, 2026.
The drug became available through LillyDirect on April 6, 2026, with broader availability through retail pharmacies and telehealth providers to follow.
Side effects include nausea, vomiting, and other gastrointestinal issues. The drug carries a boxed warning for thyroid C-cell tumors and should not be used by patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
